Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

info@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

Daily Archives: November 19, 2019

Appendix 3B, Exercise of Options

Financial Reports 2019, News & Announcements 2019By Richard Mollard November 19, 2019

191121_Exercise of Options

Recent Articles

February 15, Canine Monepantel Phase IIb Lymphoma Trial Update
February 14, 2021
February 10, LUMC Covid-19 Research Update
February 10, 2021
January 31, Top 20 Shareholders
February 1, 2021
January 27, Appendix 4C and Quarterly Update
January 27, 2021

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAustFollow

PharmAust @PharmAust·

“We think products such as MPL will happily co-exist with vaccines,” $PAA Executive Chairman, Dr Roger Aston told @StockheadAU yesterday.

https://stockhead.com.au/health/so-covid-vaccines-are-here-what-now-for-all-those-biotechs-working-on-covid-19-drugs-or-tests/

Reply on Twitter 1364338373138161666 Retweet on Twitter 13643383731381616664 Like on Twitter 13643383731381616666 Twitter 1364338373138161666

Copyright © 2020 Pharmaust. All rights reserved.

Website Design & Digital Marketing Perth by Total Click Solutions